Abstract:Even when faced with elimination, functional materials may offer new alternatives to expensive drugs. Once used to treat benign prostate hypertrophy, the US Food and Drug Administration (FDA) suspended the use of lonidamine due to the occurrence of liver problems arising from its poor pharmaceutical properties. The objectives of the present study were to develop targeting lonidamine liposomes in combination with targeting epirubicin liposomes to circumvent drug-resistant cancer. Evaluations were performed on A549 and drug-resistant A549cDDP lung cancer cells and drug-resistant A549cDDP xenografted BALB/c nude mice. A DQA-PEG2000-DSPE conjugate was incorporated onto the liposomes as a targeting molecule. The constructed targeting lonidamine liposomes and targeting epirubicin liposomes measured were approximately 80 nm. The targeting lonidamine liposomes significantly enhanced the inhibitory effect of the targeting epirubicin liposomes in the drug-resistant A549cDDP cells in a lonidamine dose-dependent manner. Mechanism studies revealed that the targeting liposomes were selectively accumulated in the mitochondria, dissipating the mitochondrial membrane potential, opening the mitochondrial permeability transition pores, and releasing cytochrome C by translocation. This initiated a cascade of caspase 9 and 3 reactions and activated the pro-apoptotic Bax protein while suppressing the anti-apoptotic Mcl-1 protein, thereby enhancing the cytotoxic effect by acting on the mitochondrial signaling pathways. The efficacy in treating the drug-resistant A549cDDP xenografted tumor model after administration of the targeting lonidamine liposomes plus targeting epirubicin liposomes was the most significant compared with the administration of the controls at comparable doses. In conclusion, targeting lonidamine liposomes could be used as a potent co-therapy with an anticancer agent to enhance the efficacy of treating drug-resistant cancer by acting on the mitochondrial signaling pathways.

A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism

A Mitochondria-Targeting Self-Assembled Carrier-Free Lonidamine Nanodrug for Redox-Activated Drug Release to Enhance Cancer Chemotherapy

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase

Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells.

The Targeting Effect of Hm2E8b–NCTD–liposomes on B-lineage Leukaemia Stem Cells is Associated with the HLF–SLUG Axis

Glutaminolysis inhibition boosts photodynamic therapy to eliminate cancer stem cells

A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells

A novel strategy to enhance inhibition of Hela cervical cancer by combining Lentinus β -glucan and autophagic flux blockage

Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.

Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance.

Gsh-Responsive Nanoprodrug To Inhibit Glycolysis And Alleviate Immunosuppression For Cancer Therapy

Mitochondrial-targeting Nanoprodrugs to Mutually Reinforce Metabolic Inhibition and Autophagy for Combating Resistant Cancer.

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment

A Novel Double-Targeted Nondrug Delivery System for Targeting Cancer Stem Cells

Lonidamine Increases the Cytotoxic Effect of 1-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea via Energy Inhibition, Disrupting Redox Homeostasis, and Downregulating MGMT Expression in Human Lung Cancer Cell Line

Discovery of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives As Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition

Cutting Off H+ Leaks on the Inner Mitochondrial Membrane: A Proton Modulation Approach to Selectively Eradicate Cancer Stem Cells

Discovery of YH677 As a Cancer Stemness Inhibitor That Suppresses Triple-Negative Breast Cancer Growth and Metastasis by Regulating the TGFβ Signaling Pathway.

Nucleus-targeted Nano Delivery System Eradicates Cancer Stem Cells by Combined Thermotherapy and Hypoxia-Activated Chemotherapy.

Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes.